Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ESRRG | P62508 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13078204 | 0.88 | PTPN1 (0.37) | PTPN1PTPN2 | |
| SCHEMBL3735415 | 0.88 | HTR2A (0.35) | PTPN1PTPN2ALDH1A1ESRRG | |
| SCHEMBL13850697 | 0.86 | PTPN1 (0.35) | PTPN1PTPN2ESRRG | |
| SCHEMBL3735481 | 0.83 | PTPN1 (0.44) | PTPN1PTPN2ALDH1A1LMNAMAPT | |
| SCHEMBL3737652 | 0.83 | PTPN1 (0.36) | PTPN1PTPN2ESRRG | |
| SCHEMBL3800605 | 0.82 | PTPN1 (0.39) | PTPN1PTPN2 | |
| SCHEMBL3743053 | 0.81 | PTPN1 (0.38) | PTPN1PTPN2MAPT | |
| Hydrochloric Acid SCHEMBL3800600 | 0.81 | PTPN1 (0.38) | PTPN1PTPN2LMNAMAPT | |
| SCHEMBL7188073 | 0.81 | PTPN1 (0.36) | PTPN1PTPN2 | |
| SCHEMBL3745490 | 0.81 | ESRRG (0.48) | PTPN1PTPN2LMNAMAPTESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | PTPN1 2/4885PTPN2 5/4885ALDH1A1 765/4885 |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | PTPN1 2/4885PTPN2 5/4885ALDH1A1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.